SMOKE-FREE-SWEDEN
PUBLIC health experts launched a major new report today (TUESDAY) to mark Sweden approaching the historic milestone of becoming Europe’s first ‘Smoke Free’ country.
Sweden is on course to drop below a 5% tobacco smoking prevalence rate in the coming months. This is the level below which the country will be considered officially ‘Smoke Free’.
No other country in the European Union is even close to replicating this achievement and none are currently on track to even achieve it by the EU’s target of 2040, in 17 years time.
The country's groundbreaking strategy to minimize the harmful effects of tobacco smoking and save lives is detailed in a new report entitled "The Swedish Experience: A roadmap for a smoke-free society," presented today at an international research seminar in Stockholm.
According to the report's authors, Sweden's approach, which combines tobacco control methods with harm minimisation strategies, could save 3.5 million lives in the next decade if other EU countries adopt similar measures.
"Quitting smoking like Sweden saves lives," says Dr. Anders Milton, one of the report's authors. "It has annually saved more than 3,400 lives in Sweden. If all other EU countries did as Sweden did, 3.5 million lives could be saved in the coming decade, in the EU alone."
Combination of tobacco control with harm minimization
The Swedish model combines recommendations in the WHO Framework Convention for Tobacco Control (FCTC), including reducing the supply and demand of tobacco, banning smoking in certain places, but it adds an important element: accepting smoke-free products as less harmful alternatives.
"It's about combining tobacco control with harm minimisation," explains Dr. Delon Human, another of the report's authors. "There are no risk-free tobacco products, but e-cigarettes, for example, are 95% less harmful than cigarettes. It is far better for a smoker to switch from regular cigarettes to e-cigarettes or nicotine pouches than to continue smoking."
Public health benefits for individual and society
The benefits of Sweden's strategy are enormous, with the country having the lowest percentage of tobacco-related diseases in the EU and a 41% lower incidence of cancer than other European countries. The report also describes how the percentage of smokers in Sweden has dropped from 15 percent to 5.6 percent of the population in 15 years, putting it on track to achieve smoke free status 17 years ahead of the EU’s 2040 target.
"Sweden has a very successful tobacco strategy that should be exported," says Professor Karl Fagerström, who also authored the report.
"It would be of enormous benefit to the world if more countries did as Sweden did with measures that reduce supply and demand while having differentiated tax rates that give smokers financial incentives to switch from cigarettes to less harmful alternatives," Dr. Fagerström added.
About the report
The report was commissioned by Health Diplomats, an international organization working to improve access to healthcare, encourage innovation and the use of harm reduction to minimize the negative impact of alcohol, food, nicotine and drugs.
The full report is available here: smokefreesweden.com/report_en
Some of the report's conclusions and suggestions for implementation in other countries.
1. Recognize smoke-free products as less harmful and that they pose significantly less risk than smoking. Encourage smokers to switch from cigarettes to less harmful alternatives.
2: Provide fact-based information. It is clear that there are no risk-free tobacco products. But, for example, e-cigarettes are 95% less harmful than cigarettes. Of course, it is better for a smoker to switch from regular cigarettes to e-cigarettes, although it is not without risk.
3: Policy decisions that make smoke-free alternatives more accessible than cigarettes. For example, differentiated taxes that give smokers financial incentives to switch from cigarettes to less harmful alternatives.
About the report's authors:
Dr. Anders Milton, formerly chairman of the Swedish Medical Association, the Swedish Red Cross and the World Medical Association.
Prof. Karl Fagerström, docent and internationally recognized expert in addiction research and smoking cessation.
Dr. Delon Human, physician specializing in global public health issues. Former advisor on public health issues to, among others, three WHO directors-general and the UN secretary-general.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005249/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
1GLOBAL Empowers Revolut to Offer Mobile Plans in Poland16.12.2025 13:04:00 CET | Press release
1GLOBAL, a technology-driven global mobile communications provider, strengthens its partnership with Revolut, expanding the leading neobank’s mobile data plan offering to the Polish market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216769985/en/ 1GLOBAL strengthens its partnership with Revolut, expanding the leading neobank’s mobile data plan offering to the Polish market. By integrating 1GLOBAL’s eSIM capability into its multi-service app, Revolut’s customers in Poland who signed up to the waitlist can now enjoy bundled mobile plans that include competitively priced domestic data plans starting at zł 25 per month (approx. €6.00 per month) with unlimited calls and texts in Poland and the EU, in just a few taps. For 1GLOBAL, this expansion marks another milestone in the company’s embedded telco services strategy. The services are trusted by more than 4,000 corporate partners across a variety of industries including fi
Dompé Doses First Patients in Europe and US in Phase 3 Studyof Isocyclosporin for Atopic Keratoconjunctivitis16.12.2025 13:00:00 CET | Press release
Atopic keratoconjunctivitis(AKC) is a chronic inflammatory disease of the eye that is frequently associated with atopic conditions, and limited disease awareness often leads to delayed or missed diagnosis. Isocyclosporin is a novel, dual inhibitor oftwo critical immunepathways in ocular inflammation like AKC. Dompé, a leading biopharmaceutical company with operations in Italy and the U.S., announced the first patients have been enrolled in a Phase 3 study of Isocyclosporin for the treatment of atopic keratoconjunctivitis (AKC). Isocyclosporin is a dual inhibitor of transient receptor potential (TRP) cation channel, mucolipin subfamily, member 2 (TRPML2) and calcineurin, key regulators of immune and inflammatory response in chronic inflammatory eye diseases. The Phase 3 trial is a multicenter, randomized, double-masked study comparing isocyclosporin against vehicle control in improving ocular signs and symptoms after six weeks of treatment. “This milestone underscores Dompé’s commitment
Visa Launches Stablecoin Settlement in the United States, Marking a Breakthrough for Stablecoin Integration16.12.2025 13:00:00 CET | Press release
With more than $3.5B in annualized stablecoin settlement volume1, Visa brings USDC settlement to U.S. institutions. Visa Inc. (V) today announced the launch of USDC settlement in the United States, marking a major milestone in the company’s stablecoin settlement pilot program and strategy to modernize its settlement layer underpinning global commerce. For the first time, U.S. issuer and acquirer partners can settle with Visa in Circle’s USDC, a fully reserved, dollar-denominated stablecoin. With USDC settlement, issuers can benefit from faster funds movement over blockchains, seven‑day availability and enhanced operational resilience across weekends and holidays - without any change to the consumer card experience. Initial banking participants include Cross River Bank and Lead Bank, which have started settling with Visa in USDC over the Solana blockchain. Broader availability in the U.S. is planned through 2026. Additionally, Visa is a design partner for Arc, a new Layer 1 blockchain d
Volante Technologies Customers Successfully Navigate Critical Regulatory Deadlines for EU SEPA Instant and Global SWIFT Cross-Border Payments16.12.2025 10:00:00 CET | Press release
PaaS leader ensures seamless migrations and uninterrupted payment operations Volante Technologies, the global leader in Payments as a Service (PaaS), today announced it has successfully upgraded its clients to meet the latest SEPA Instant Payments Regulation (IPR) and SWIFT SRG 2025 mandate, which came into effect October 9th and November 22nd, 2025, respectively. This announcement follows the major FedISO upgrade in July, which shifted trillions of dollars in payments to the new ISO 20022 messaging format. SEPA IPR is a significant European milestone, requiring payments to be made within 10 seconds and at any time of day, throughout the year. Adoption was mandatory and Eurozone banks were compelled to meet strict deadlines, with January 9th, 2025 the deadline for receiving incoming instant payments and October 9th the deadline for sending outgoing instant payments. The latest deadline impacted more than 700 banks across Europe, with non-compliance penalties reaching at least 10% of an
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
